Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RPC4046 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| RPC4046 Low Dose | EXPERIMENTAL | intravenous (IV) infusion only once at first dose, 2 subcutaneous (SC) injections weekly for 16 weeks, low dose |
| RPC4046 High Dose | EXPERIMENTAL | intravenous (IV) infusion only once at first dose, 2 subcutaneous (SC) injections weekly for 16 weeks, high dose |
| Placebo | PLACEBO_COMPARATOR | intravenous (IV) infusion only once at first dose, 2 subcutaneous (SC) injections weekly for 16 weeks |
| Name | Type | Description |
|---|---|---|
| RPC4046 | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: * Histologic evidence of EoE * Clinical symptoms of EoE including dysphagia Exclusion Criteria: * Primary causes of esophageal eosinophilia other than EoE
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AstraZeneca PLC | AZN | 1 | PHASE3 | Tezepelumab |
| Regeneron Pharmaceuticals, Inc. | REGN | 3 | PHASE3 | dupilumab |
| Phathom Pharmaceuticals, Inc. | PHAT | 1 | PHASE2 | Vonoprazan |
| Eupraxia Pharmaceuticals, Inc. | EPRX | 1 | PHASE1 | EP-104GI |
| Sanofi SA Sponsored ADR | SNY | 1 | - | Dupilumab |
| Smith & Nephew plc Sponsored ADR | SNN | 1 | - | Undisclosed |
RPC4046 is an investigational small molecule being developed for the treatment of Eosinophilic Esophagitis, a chronic allergic inflammatory condition of the esophagus. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
RPC4046 is being developed by Bristol-Myers Squibb Company, which trades on the New York Stock Exchange under the ticker symbol BMY. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with Eosinophilic Esophagitis.
RPC4046 is in Phase 2 clinical development. It has completed one Phase 2 trial, and it remains an investigational drug that is not yet approved for any use. The completed trial was a dose-ranging study in patients with Eosinophilic Esophagitis.
RPC4046 has one completed clinical trial, identified as NCT02098473, titled "Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis." This Phase 2 study enrolled 100 participants and was conducted in the United States, Canada, and Switzerland.
RPC4046 is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for Eosinophilic Esophagitis. The drug has completed a Phase 2 trial, but it has not received marketing approval from the FDA or any other regulatory agency.